463P Evaluation of pharmacodynamic (PD) biomarkers in advanced cancer patients treated with oxidative phosphorylation (OXPHOS) inhibitor, OPC-317 (OPC)
Eu J, Yadav K, Lim Y, Hirpara J, Kong L, Ng Z, Lee V, Lee S, Tan D, Soo R, Chee C, Yong W, Sundar R, Lim J, Wang L, Ohi N, Tsunoda T, Pervaiz S, Goh B, Wong A. 463P Evaluation of pharmacodynamic (PD) biomarkers in advanced cancer patients treated with oxidative phosphorylation (OXPHOS) inhibitor, OPC-317 (OPC). Annals Of Oncology 2019, 30: v174. DOI: 10.1093/annonc/mdz244.025.Peer-Reviewed Original ResearchMitochondrial membrane potentialSerum metabolomeHER2+ breast cancerOncogene-addicted tumorsDose-finding phaseClinically tolerable dosesCancer stem cellsNon-significant riseG3/4 toxicitiesOxidative phosphorylation inhibitionSignificantly with treatmentGIST patientsTolerated doseTumor biopsiesImmunohistochemistry expressionCopy numberOxidative phosphorylationSerum lactateBreast cancerClinical developmentDrug resistanceMerck SeronoDose levelsDay 1Pathway inhibitor